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ABSTRACT
Non-small-cell lung cancer (NSCLC) is the most common cancer in men and the second most common in fe-
males. In previous years the significance of some molecular disorders in pathogenesis NSCLC was proven and 
the value of targeted therapies in the treatment of patients was documented. In subjects with abnormalities of 
EGFR, ALK and ROS1 genes, appropriate tyrosine kinase inhibitors (TKIs) may be used. The use of these drugs 
in the first and second treatment lines has affected a significant improvement in the prognosis in this subgroup 
of patients. The article presents mechanisms of action and data on the clinical value of lorlatinib, brigatinib and 
dacomitinib in the treatment of patients with advanced lung of lung cancer.
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Introduction
Lung cancer is the most commonly diagnosed cancer 
in men and the second, after breast cancer, most common 
cancer in women. At the same time, it is the main cause 
of cancer deaths among both men and women (about 
1.7 million per year) [1]. In about 80–85% of patients, 
non-small cell lung cancer (NSCLC) is diagnosed [2]. 
The generalised stage of the disease is initially found in 
more than 40% of patients [2]. Histological type and oth-
er pathomorphological factors are now routinely taken 
into account when choosing the type of treatment. In re-
cent years, the importance of some molecular disorders 
in the pathogenesis of NSCLC has been demonstrated 
and the value of targeted therapies in the treatment of 
patients with this diagnosis has been shown. Currently, 
the standard is an individual approach in choosing the 
optimal procedure. In patients with abnormalities of 
epidermal growth factor receptor (EGFR) gene, ana-
plastic lymphoma kinase (ALK) gene, and ROS1 gene 
it is possible to use appropriate tyrosine kinase inhibi-
tors. The use of these drugs in the first and second line 
of treatment has resulted in significant improvement 
of prognosis in this subgroup of patients. The observed 
results of treatment confirmed the validity of searching 
for new, even more effective molecular target drugs, also 
effective in patients with developed resistance to earlier 
therapies or in the group of patients with metastases to 
the central nervous system (CNS). The article presents 
the current state of knowledge and potential uses of 
lorlatinib, brigatinib, and dacomitinib — next genera-
tion eGFR ALK/ROS1 tyrosine kinase inhibitor (TKI).
Lorlatinib
Pharmacological characteristics of lorlatinib
Lorlatinib (PF-06463922) is a third-generation 
low-molecular-weight inhibitor of ALK and ROS1 TKI. 
It is characterised by high affinity and strong inhibition 
of kinase. It also shows inhibitory action in the case 
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of G1202R mutation — the most common secondary 
mutation responsible for the development of resistance 
to ALK TKI of previous generations. Lorlatinib has 
a macrocyclic structure, which distinguishes it from other 
ALK inhibitors. Thanks to its structure, it has greater 
metabolic stability and the ability to pass through the 
blood-brain barrier. Lorlatinib is an orally bioavailable 
drug. After a single dose (10–200 mg), it is absorbed, 
reaching its maximum plasma concentration within 
1–2 hours. The elimination phase half-life of lorlatinib 
ranges from 19.0 to 28.8 hours at doses of 10, 50, 75, 
100, and 200 mg [3]. Results of in vitro and in vivo studies 
indicate that lorlatinib may change the pharmacokinetics 
of other drugs that are metabolised by P450 cytochrome 
isoenzymes and are administered at the same time. 
Therefore, according to the Phase II study, concomi-
tant use of CYP3A inhibitors is not allowed for at least 
12 days before the first dose of lorlatinib [3].
Clinical trials with lorlatinib
Phase I study
The phase I multi-centre study was designed to 
determine the pharmacokinetics and maximum toler-
able dose, and to assess the adverse effects of lorlatinib 
in patients with advanced NSCLC with current ALK 
(77%) or ROS1 (23%) gene rearrangement [4]. Other 
eligibility criteria included performance status according 
to the eastern Cooperative Oncology Group (eCOG 
0–1) and proper function of organs. In the 54 patients 
enrolled in the study, two or more TKI therapies were 
previously used in 28 patients and 39 (72%) had me-
tastases to the CNS. Lorlatinib was administered orally 
at doses from 10 to 200 mg once daily or 35 to 100 mg 
twice daily. A well-tolerated dose — recommended for 
further studies — was set at 100 mg once daily. Among 
41 ALK-positive patients the objective response rate 
(ORR) was found in 19 patients [46%; 95% confidence 
interval (CI) 31–63], including 11 out of 26 who previ-
ously used TKI (42%; 95% CI 23–63). In ROS1-positive 
patients, including seven patients previously treated with 
crizotinib, ORR was obtained in six patients (50%; 95% 
CI 21–79). Out of 24 patients with measurable target 
lesions in the CNS (46%; 95% CI 26–67) 11 had an 
intracranial objective response to the treatment.
Phase II study
In 2017, during the 18th World Conference on Lung 
Cancer, the results of the Phase II study were presented, 
in which 275 patients were included. The participants 
were divided into six cohorts depending on the previ-
ously applied therapy (Table 1) [5]. For five cohorts of 
197 patients who previously received ALK inhibitors in 
different configurations, the percentage of ORR ranged 
from 33% (first line of treatment for ALK TKI other 
than crizotinib ± chemotherapy) to 74% (patients pre-
viously receiving only crizotinib). Objective intracranial 
responses in patients with CNS metastases ranged from 
39% (three treatment lines ALK TKI ± chemotherapy) 
to 75% (crizotinib ± chemotherapy). The percentage of 
ORR was 90% in patients receiving lorlatinib as the 
first-line of treatment [5].
The American Food and Drug Administration 
(FDA) recognised lorlatinib as a breakthrough therapy 
in patients with advanced ALK-positive NSCLC [3, 6]. 
The definition of “breakthrough therapies” aims at 
accelerating the development and review of a potential 
new drug if it is intended to treat a serious or life-threat-
ening disease, and initial clinical evidence suggests that 
the drug can be significantly effective compared to 
existing therapies [6].
Phase III study
A phase III study (CROWN) is currently underway, 
in which lorlatinib and crizotinib efficacy is compared 
in the first line of treatment of NSCLC with ALK rear-
rangement [7]. Patients are randomly assigned to arm 
A (lorlatinib 100 mg, 1 × daily) or arm B (crizotinib 
250 mg, 2 × daily). The primary endpoint of the study 
is the evaluation of the influence of these therapies on 
the progression-free duration. Among the secondary 
endpoints, the percentage of objective intracranial re-
sponses in patients with measurable metastases to the 
CNS will also be assessed.
Table 1. Phase II study results with lorlatinib [5]
Earlier therapy n ORR — n (%) N (metastases to CNS) ORR (metastases to CNS) 
— n (%)
Without treatment 30 27 (90) 8 6 (75)
Crizotinib 27 20 (74) 17 10 (59)
Crizotinib + CHTH 32 21 (66) 20 15 (75)
Diffrent ALK TKI ± CHTH 27 9 (33) 12 5 (42)
2 lines ALK TKI ± CHTH 65 27 (42) 45 25 (56)
3 lines ALK TKI ± CHTH 46 16 (35) 38 15 (39)
CHTH — chemotherapy; ORR — objective response rate; ALK — anaplastic lymphoma kinase; TKI — tyrosine kinase inhibitor; CNS — central nervous system
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Efficacy in patients with metastases to the central 
nervous system
Metastases to the brain are a common complication 
of cancer, and the effectiveness of drugs is significantly 
reduced in this area. Retrospective analysis showed that 
20–30% of all NSCLC patients with ALK rearrangement 
had metastases in the CNS at the time of diagnosis (com-
pared to 10–20% of patients with NSCLC regardless of 
ALK status) [8]. This number increases to 45–75% dur-
ing the disease in patients using ALK inhibitors, which 
indicates that the disease in the CNS is a major problem 
in patients with ALK rearrangement. This is due to the 
presence of the blood-brain barrier. It is a semi-permeable 
barrier separating blood from extracellular CNS fluid. It 
consists of closely connected endothelial cells. It pre-
vents the penetration of harmful substances into the 
brain, at the same time blocking the supply of many 
medicinal substances to it. The blood-brain barrier is not 
only a physical barrier to most substances, but thanks 
to P-glycoprotein and multidrug resistance proteins it 
also actively removes drugs [9]. The limitation for the 
first-generation ALK inhibitor crizotinib were frequent 
recurrences of the disease in the CNS. Next-generation 
inhibitors are characterised by better penetration to 
the CNS. Lorlatinib was designed to penetrate through 
the blood-brain barrier. This was confirmed by the pre-
clinical studies of Collier et al. in which the penetration of 
lorlatinib was evaluated by positron emission tomography 
(PeT) using carbon and fluorine marking [10]. In phase 
I clinical trials 46% of patients with measurable CNS 
metastases received an objective intracranial response to 
treatment [4]. The Phase II study showed high systemic 
and intracranial ORR (Table 1) in patients treated with 
the first line of treatment as well as in those receiving 
TKI ALK [5].
Efficacy in patients with drug resistance
Regardless of the type of TKI ALK used, disease 
progression occurs in patients treated with these drugs 
about 12 months after the onset of therapy [8]. However, 
the mechanisms of molecular progression vary. In about 
50–60% of patients with acquired resistance to first-gene- 
ration ALK TKI (crizotinib) activation of other cellular 
transmission pathways starting with eGFR or IGF1-R, 
mutation in the KRAS gene, or amplification of ALK 
and KIT genes occurs [11]. However, in 30–40% they 
depend on the selection of a clone cell with a point mu-
tation in the ALK gene [8, 11]. Lorlatinib in pre-clinical 
studies showed activity against most known resistance 
mutations. Phase I and II studies confirmed its high ef-
ficacy in patients with advanced ALK-positive NSCLC, 
most of whom had previously been treated. Shaw et al. 
evaluated circulating DNA and tumour tissue samples 
from patients previously treated with ALK TKI, who 
took part in the phase II study [12]. samples were ana-
lysed from patients in five cohorts (Table 1): previously 
just crizotinib, previously crizotinib + chemotherapy 
or any other ALK TKI ± chemotherapy, two previous 
ALK TKI ± chemotherapy, and three previous ALK 
TKI ± chemotherapy. Samples were evaluated for the 
presence of mutations. A total of 75 mutations were 
detected, with G1202R being the most frequent (25%), 
followed by F1174 (15%), L1196M (15%), G1269A 
(11%), and I1171 mutations (8%). Responses were 
observed in 64% of patients whose samples contained 
more than one mutation in the ALK kinase domain. 
Also, 42% of patients without detectable mutation re-
sponded to lorlatinib. Mutation of G1202R was often 
observed in patients who earlier received 2 or 3 ALK 
TKI treatment lines [12]. 
Lorlatinib has been designed to overcome resistance 
to earlier therapy, but resistance may also occur when 
using this drug. Shaw et al. also demonstrated a new 
mechanism of resistance to this drug. In patients resist-
ant to lorlatinib, they detected a double mutation (ALK 
C1156Y-L1198F), which if present, surprisingly, restores 
sensitivity to crizotinib [13].
Adverse effects
Hypercholesterolaemia (72%), hypertriglyce-
ridaemia (39%), peripheral oedema (39%), and 
peripheral neuropathy (39%) were the most common 
side effects of lorlatinib [4]. In the Phase I study, level 
2 CNS toxicity was found in the form of slowed speech 
and mental activity but also difficulty in finding words. It 
appeared in patients receiving 200 mg of lorlatinib once 
a day — dose-limiting toxicity (DLT) [4]. In the phase II 
study, third- and fourth-degree adverse effects related 
to treatment were found, which included hypercholes-
terolaemia (16%) and hypertriglyceridaemia (16%) [5]. 
No treatment-related deaths were reported. The toxicity 
of lorlatinib differs from that reported for other ALK 
TKIs. Hepatotoxicity (increased activity of aspartate 
transaminase or alanine transaminase) and gastrointes-
tinal disorders (nausea, vomiting, diarrhoea) are mainly 
associated with other inhibitors and occur much less fre-
quently with lorlatinib [3]. The side effects of lorlatinib 
do not affect the quality of life of patients. About 43% 
of treated patients report improved quality of life [5].
Brigatinib
Pharmacological characteristics of brigatinib
Brigatinib (AP26113, Alunbrig) is another oral TKI 
ALK. In preclinical studies with use of ALK-positive 
cell lines brigatinib showed a 12-fold greater potency 
than crizotinib [14]. It was characterised by a high 
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degree of selectivity, inhibiting only 11 kinases (from 
289 evaluated), including ROS1, FLT3, mutant variants 
of FLT3 (D835Y), and eGFR (L858R). Whilst brigatinib 
demonstrated a lower anti-eGFR (including T790M re-
sistance mutation), anti-IGF1R, and anti-INSR activity, 
it did not show activity against the MeT pathway [14]. 
Compared to crizotinib, brigatinib showed an activity 
advantage and inhibitory profile against all assessed sec-
ondary ALK mutations, including G1202R [14]. After ad-
ministration of a single oral dose (30–240 mg) the median 
time to maximum drug concentration (Tmax) is 1–4 hours 
[16]. The mean elimination half-life in plasma is 25 hours, 
and hepatic excretion is the main route of drug elimina-
tion [15]. In in vitro studies, brigatinib has been shown to 
be metabolised by cytochrome CYP2C8 and CYP3A4, 
and, to a much lesser extent, by CYP3A5. Brigatinib is 
eliminated mainly through faeces [16].
Clinical trials with brigatinib
Phase I/II study
The multicentre phase I/II study was designed to 
determine the pharmacokinetics and the maximum tole-
rated dose, and to evaluate the side effects of brigatinib. 
In total 66 patients were enrolled with performance 
status 0–1 according to eCOG (eastern Cooperative 
Oncology Group) scale, with measurable change accord-
ing to ReCIST 1.1 criteria. The study involved patients 
with asymptomatic CNS metastases. 
Brigatinib was given orally at the doses of 30 mg, 
60 mg, 90 mg, 120 mg, and 180 mg once daily. In the 
phase II study the doses of 90 mg, 180 mg, and 180 mg 
were used preceded by a seven-day initial period in 
which a dose of 90 mg was administered. In the phase 
II study patients were divided into five cohorts — pa-
tients with NSCLC and ALK gene rearrangement pre-
viously not treated with ALK TKI (cohort 1), patients 
with NSCLC and ALK gene rearrangement previously 
treated with crizotinib (cohort 2), patients with NSCLC 
and with T790M mutation in EGFR gene treated with 
TKI (cohort 3), patients with other cancers with con-
comitant disorders in ALK and ROS1 gene (cohort 4), 
and patients with CNS metastases both treated and not 
treated with crizotinib [17].
The endpoint of the first part of this study was to 
determine the tolerated dose, and in the second part, 
the ORR. In the second part of the study a response was 
achieved by 100% of the patients in cohort 1, 74% of 
the patients in cohort 2 (31 out of 42 patients), none of 
the patients in cohort 3, 17% of the patients in cohort 
4, and 83% of the patients in cohort 5 [17].
Phase II study
The study involved 222 patients from 71 sites ran-
domly assigned (1:1) to arm A (brigatinib 90 mg once 
daily) and arm B (brigatinib 180 mg once daily with pre-
vious seven-day initial period in which a dose of 90 mg 
was used) [18]. Patients were stratified according to 
the CNS metastases (present or absent) and the type of 
response to previously used crizotinib (complete or par-
tial response). The primary endpoint was ORR and the 
secondary endpoint was PFS and overall survival (OS). 
In arm A the ORR was 45% (97.5%, range from 34% 
to 56%), including one patient with complete response 
(CR), and in arm B 54% (97.5%, range from 43% to 
65%), including four patients achieving CR. In arm A, 
PFS was 9.2 months, in arm B it reached 12.9 months 
[18]. The one-year OS rate was 71% and 80% in A and 
B arm, respectively.
Phase III study
From April 2016 to August 2017 at total of 275 pa-
tients in 124 sites were randomised (1:1) to the arm 
receiving crizotinib or brigatinib [19]. 
Patients were stratified according to the CNS me-
tastases (present or absent). Patients in the brigatinib 
group received a 180-mg dose once daily (with a prior 
seven-day period with a dose of 90 mg) in 28-day cycles, 
and the patients in the crizotinib arm received 250 mg 
of the drug twice daily in 28-day cycles. In both arms the 
treatment was continued until the disease progressed. 
Patients in the crizotinib arm were allowed to cross-over 
to the brigatinib group after disease progression. The 
primary endpoint of the study was PFS. Secondary end-
points included the overall ORR and, in patients with 
measurable CNS, metastases. 
The first analysis of the study showed the superior-
ity of brigatinib over crizotinib in 12-month PFS (67% 
vs. 43%). ORR in the brigatinib arm was 71% vs. 60% 
in the crizotinib arm.
Efficacy in patients with metastases in the central 
nervous system
In the ALTA study the ORR in the group of patients 
with baseline measurable CNS metastases assessed by 
an independent expert committee reached 42% in arm 
A (11 out of 26 patients) and 67% in arm B (12 out of 
18 patients) [18]. Among 39 patients with measurable 
lesions in CNS participating in a phase III clinical study, 
intracranial responses were achieved by 78% patients 
in the brigatinib group compared with 29% patients in 
the crizotinib group [19].
Adverse events
The most common adverse events reported during 
brigatinib treatment are summarised in Table 2. 
In the ALTA study, 6% of patients experienced 
pulmonary adverse reactions in general (3% grade ≥ 3; 
including interstitial lung disease [ILD], pneumonia, 
and dyspnoea). These events were reported during the 
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Table 2. Adverse events of brigatinib [15, 19]
Study Patients AE G1–2 AE G3–4
I/II 71 Nausea (53%)
Fatigue (43%)
Diarrhoea (41%)
↑ lipase (9%)
Dyspnoea (6%)
Hypertension (5%)
ALTA A — 112/B — 110 Nausea (33%/40%)
Diarrhoea (19%/38%)
Headaches (28%/27%)
Cough (18%34%)
↑ CPK (3%/9%)
Hypertension (6%/6%)
Pneumonia (3%/5%)
ALTA-1L 137 Diarrhoea (49%)
↑ creatinine (39%)
Nausea (26%)
Cough (25%)
Hypertension (23%)
↑ creatinine (16%)
↑ lipase (13%)
Hypertension (10%)
↑ — elevated level; AE — adverse event; CPK — creatine phosphokinase
early treatment period (median time to onset — two 
days) [16, 18]. early pulmonary adverse events also 
occurred in patients recruited to the dose escalation 
study — including three fatal cases (hypoxia, acute 
respiratory distress syndrome, and pneumonia). In ad-
dition, 2.3% of patients in ALTA study had pneumonia 
at a later stage of treatment, and in two patients it was 
grade 3 pneumonitis [16]. Interstitial lung disease or 
pneumonia was found in 4% of patients treated with 
brigatinib in the ALTA-1L study (2% in the crizotinib 
treated group) [19].
In 2017, the FDA approved the accelerated registra-
tion of the drug in the treatment of patients who have 
progressed after crizotinib treatment or with intolerance 
of this drug (breakthrough therapy).
Dacomitinib
Pharmacological characteristics of dacomitinib
Dacomitinib (PF-299804) is a strong, highly selec-
tive, second-generation oral TKI that irreversibly blocks 
eGFR/HeR1, HeR2, and HeR4. It inhibits the tyrosine 
kinase activity by binding at the ATP binding site, which 
results in covalent modification of cysteine in the ATP 
binding cassette. The irreversible and highly selective 
properties of dacomitinib cause a persistent suppression 
of the tyrosine kinase receptor activity. Dacomitinib is 
absorbed orally with a median time of maximum con-
centration (Tmax) in the range of five to 12 hours. The 
average half-life is 54 to 90 hours [21].
Clinical trials with dacomitinib
Phase I study
The phase I multi-centre study was designed to de-
termine pharmacokinetics and maximum tolerable dose, 
and to assess the adverse effects of dacomitinib. It was 
attended by 57 patients previously treated with erlotinib 
or gefitinib with advanced NSCLC with eCOG 0–1 ef-
ficiency and normal organ function. Patients received 
dacomitinib at a dose of 0.5 to 60 mg once a day. 
A well-tolerated dose — recommended for further 
studies — was set at 45 mg once daily. In 33 patients 
the presence of EGFR gene activation mutation was 
confirmed, and in four patients T790M resistance muta-
tion was detected. Out of 57 patients, 56% had ORR of 
whom four had partial response (PR) and 28 had stable 
disease (SD) [22].
Phase II study
The study involved 89 patients, 85% of whom 
were patients with confirmed mutation of eGFR gene 
activation (in 25 patients, deletion in 19 exon was 
detected, and in 20, insertion in exon 21). In 15% of 
patients, other types of mutations were identified; 15% 
of the studied population were patients without EGFR 
gene mutations. The average observation period was 
24.8 months.
ORR in the whole population was 53.9%. In 47 pa-
tients (53%) PR was achieved, and in one CR — com-
plete response — was noted. The percentage of PFS 
was 11.5 months. In the population of patients with 
confirmed activating mutation of EGFR gene, PFS was 
18.2 months with no significant differences between 
patients with exon 19 deletion (16.6 months) and exon 
21 insertion (18.3 months). PR was achieved in 34 out 
of 45 patients with mutation (76%). 
The mean duration of treatment in the whole 
evaluated population was 9.2 months, and in the 
population with confirmed activation mutation it was 
16.5 months. The most common side effects were diar-
rhoea (93%) and acne-like rash (78%). A promising im-
provement in PFS was observed in patients with eGFR 
gene activation mutation treated in the first line [22]. 
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For comparison, in studies with reversible TKI, 
the first-generation PFS median in the population of 
patients with EGFR mutation was about 9–11 months 
[23, 24]. In a phase III study for afatinib, the PFS median 
was about 13 months in patients with mutation of EGFR 
gene activation [25].
Phase III study
From May 2013 to March 2015, in 71 centres, 452 pa-
tients were recruited, who were assigned in a ratio of 
1:1 to one of two arms: the first arm was dacomitinib 
and the second was gefitinib (Table 3) [26]. Patients were 
stratified according to their race (Asian vs. non-Asian) 
and type of EGFR activating mutation (deletion in exon 
19 vs. insertion in exon 21). In the first arm patients re-
ceived dacomitinib 45 mg once a day in 28-day cycles, and in 
the second arm patients received gefitinib 250 mg once a day 
in 28-day cycles as well. In both arms the treatment was 
continued until progression of the disease. Treatment 
after progression was allowed in case of clinical benefit. 
The primary end-point was PFS. Secondary end-points 
incuded time to treatment failure (TTF) and OS. 
In the arm with dacomitinib PFS was 14.7 months, 
and in the arm with gefitinib — 9.2 months.
In the group of patients with deletion of exon 19, 
76% of patients with dacomitinib and 70% of patients 
with gefitinib received ORR.
In the group of patients with exon-21 mutation, this 
percentage was 73% in the arm receiving dacomitinib 
and 74% in the arm that received gefitinib.
The first analysis of the study in July 2016 showed 
that dacomitinib was superior to gefitinib in the first-line 
of treatment of patients with advanced NSCLC with 
activating mutation of EGFR gene in terms of PFS. The 
OS data did not reach maturity [26].
Table 3. Characteristics of patients — phase III study 
ARCHER 150 [26]
Data Dacomitinib 
(n = 227)
Gefitinib 
(n = 225)
Age median (years) 62 (28–87) 61 (33–86)
< 65 133 140
> 65 94 85
Men 81 100
Women 146 125
ECOG
0 75 62
1 152 163
Smoking status
Never 147 144
Current 15 19
Prior 65 62
Exon
19 134 133
21 93 92
ECOG — Eastern Cooperative Oncology Group
100
90
80
70
60
50
40
30
20
10
0 6 12 18 24 30 36 42 48
HR 0.760; 95% Cl 0.582–0.993; p = 0.0438 
Number of deaths
Median (95% CI) OS, months
Dacomitinib 
(n = 227) 
Gefitinib 
(n = 225) 
103
34.1 (29.5–37.7) 
117
26.8 (23.7–32.1)
O
S
 (
%
)
Time (months)
Dacomitinib 227 206 188 167 138 77 14 3 0
Gefitinib 225 213 186 144 113 63 12 3 0 
Figure 1. Overall survival time (OS) in the phase III ARCHER 150 study [26]
A second analysis in February 2017 showed an im-
provement in OS in favour of dacomitinib (34.1 months 
vs. 26.8 months) (Fig. 1). 
In the group of patients with deletion in the 19 exon 
the mean OS was 34.1 months in the arm with dacomi-
tinib; in the arm with gefitinib no OS was achieved. 
In the group of patients with exon-21 mutation, the 
mean OS was 32.5 months in the dacomitinib arm and 
23.2 months in the arm with gefitinib. In the analysis 
of subgroups concerning race, the mean OS in the 
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non-Asian population was 29.5 months in the arm of 
patients receiving dacomitinib, and 20.6 months in 
the arm of patients treated with gefitinib. In the Asian 
population these results were as follows: in the arm 
with dacomitinib OS was 34.2 months, and in the arm 
with gefitinib it was 29.1 months. During the 30-month 
observation period, the percentage of survivors was 
56.2% in the arm with dacomitinib and 46.3% in the 
arm with gefitinib. 
Dacomitinib is the first second-generation inhibitor 
that has significantly improved survival in advanced 
NSLCL patients with activating mutation of the EGFR 
gene [27].
Conclusions
The treatment of patients with NSCLC is still in 
progress. It concerns both deepening of knowledge 
about the cancer itself as well as the development of 
new therapeutic methods. The progress in basic sciences 
resulting in better understanding of cancer biology has 
contributed to the development of molecular target 
therapies. Their use in the first- and second-line of treat-
ment has enabled us to achieve significant improvement 
in the prognosis of selected patients. The results confirm 
the legitimacy of searching for new, even more effective 
molecular target-oriented therapies, also effective in 
patients with developed resistance to earlier therapies 
or in the group of patients with metastases to the CNS 
and with previously very poor.
Lorlatinib is a third-generation ALK//ROS1 TKI, 
which showed significant activity in preclinical studies. It 
is active in patients with resistance to other ALK inhibi-
tors (it showed anticancer effects in various resistance 
mutations, including the difficult-to-treat ALK G1202R 
mutation), and it is also characterised by the ability to 
penetrate the blood-brain barrier. Lorlatinib is a drug 
currently in clinical trials, so it has not been registered 
yet in any indication. The breakthrough therapy status 
granted the by the FDA was based on the efficacy 
and safety data from the Phase I and Phase II clinical 
trials. Recruitment for an open, randomised, bi-armed 
phase III CROWN clinical trial comparing lorlatinib 
with crizotinib in the first-line of treatment in patients 
with metastatic NSCLC with the presence of ALK gene 
rearrangement has been started. 
Another ALK TKI is brigatinib. In 2017, the FDA 
approved the accelerated registration of the drug in 
the treatment of patients who had progression after 
crizotinib treatment or with intolerance of this drug 
(breakthrough therapy). Then, during the 19th WCLC 
and in the full-paper publication, preliminary results of 
the phase III ALTA-1L study were presented. Brigatinib 
compared to crizotinib significantly prolonged PFS in 
patients with ALK-“positive” NSCLC, previously un-
treated with ALK inhibitors. Brigatinib was also associ-
ated with an improvement of intracranial response rate.
Dacomitinib — a highly selective second-generation 
TKI that irreversibly blocks eGFR/HeR1, HeR2, and 
HeR4 — is the first kinase inhibitor that has signifi-
cantly improved survival in advanced NSCLC patients 
with mutation of EGFR gene activation. This review 
shows that dacomitinib should be considered as one 
of the standard drugs in the first line of treatment in 
patients with NSCLC with a confirmed mutation of 
EGFR gene activation.
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